Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength

Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.

Summary aggregated from CNBC's public RSS feed. The full reporting belongs to CNBC — please read it on their site.